Cobalis Corp. Signs Agreement with Trendtrade International to Commenc

    Pharmaceutical Writers/Business Editors

    IRVINE, Calif.--(BUSINESS WIRE)--March 22, 2005--Cobalis Corp. (OTC Bulletin Board: CLSC), a pharmaceutical company specializing in the development of anti-allergy medications, announced today that the Company has signed a comprehensive marketing consulting agreement with Sydney, Australia-based Trendtrade International Pty. to be the Company's representative/partner for Australian marketing. Under this agreement, Cobalis has engaged the extensive services of Trendtrade to assist the Company with all aspects of preparing to bring its anti-allergy product PreHistin to market in Australia later in 2005.
    The process of marketing the Company's ground-breaking allergy prevention product in Australia comprises several key steps, each of which Trendtrade will facilitate under the agreement. These steps include, among others, getting the product listed by the Australian TGA (Therapeutic Goods Administration), the Australian regulatory agency that controls the local marketing of healthcare products, and selecting and signing a definitive distribution agreement with one or more major OTC distributors in Australia.
    In addition, Trendtrade will assist and advise the Company in all phases of preparing to launch and support sales of PreHistin in Australia, including competitive market analyses, preparation of business and marketing plans, pricing, packaging, labeling, market entry, brand management and local marketing strategies. Trendtrade will also facilitate the review and selection of appropriate master distributors, negotiations towards definitive distribution rights agreements and ongoing local liaison with selected distributors.
    Said Cobalis CEO Chas Radovich: "We are very excited to take this major step forward towards commercializing our anti-allergy product internationally. Following extensive review we have selected Trendtrade International as the best local partner firm to assist us in obtaining a TGA listing and bringing PreHistin successfully into the Australian market. Their knowledge, experience and expertise will greatly enhance our ability to commence international revenue generation quickly. We are optimistic that we can achieve our goal to get PreHistin on Australia shelves in 2005."
    Trendtrade International executive Lance Kalish said: "We are delighted to have been chosen by Cobalis Corp. as their Australian representative and are highly motivated and confident about assisting the Company in successfully commercializing PreHistin in the Australian market. The anti-allergy market is one of the largest over-the-counter segments in Australia and we strongly believe that with the right partner PreHistin can become a household name for Australian allergy sufferers in a reasonably short period of time."

    ABOUT COBALIS CORP. -- PREHISTIN(TM)

    Headquartered in Irvine, California, Cobalis Corp. is an over-the-counter pharmaceutical company. Its flagship product, PreHistin, designed to prevent the primary cause of airborne allergies, is currently in Phase III clinical trials and initial marketing in the U.S. will commence upon final FDA marketing approval. The U.S. anti-allergy medication market was $7.2 billion in 2003 and is expected to exceed $10 billion by 2010. PreHistin, "the world's first pre-histamine," has shown in previous studies to modulate the body's level of the protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin appears to have essentially no risks of adverse effects to the general population, including sedation and drowsiness found in many of the allergy products currently available.

    ABOUT TRENDTRADE INTERNATIONAL

    Trendtrade International is a business development and export management firm offering international product manufacturers and distributors global trading solutions in sourcing, commercializing, launching and managing premium brands and products in the Pharmaceutical, OTC, and Health & Beauty sector within new international markets. Trendtrade carefully selects and builds brands that are market leaders in their product category and have global market potential. Based in Sydney Australia, Trendtrade has an established network of retail, wholesale, and specialist distributors providing distribution through pharmacy, grocery and other mass market channels in various territories throughout the world, including Australia and New Zealand, United Kingdom, South East Asia, Middle East, Canada and Southern Africa.

    SAFE HARBOR

    Safe Harbor Statement: Statements in this press release other than statements of historical fact, including statements regarding the company's plans, beliefs and estimates as to projections are "forward-looking statements". Such statements are subject to certain risks and uncertainties, including factors listed from time to time in the company's SEC filings, and actual results could differ materially from expected results. These forward-looking statements represent the company's judgment as of the date of this release. Cobalis Corp. does not undertake to update, revise or correct any forward-looking statements.

--30--ML/ny*

CONTACT: Cobalis Corp. Investor Relations: Chas Radovich, 949-757-0001 Fax: 949-757-0979 investor.relations@cobalis.com

KEYWORD: CALIFORNIA AUSTRALIA INTERNATIONAL ASIA PACIFIC INDUSTRY KEYWORD: BANKING MARKETING AGREEMENTS SOURCE: Cobalis Corp.

Copyright Business Wire 2005